Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Acyclovir and postherpetic neuralgia.

P Klenerman1, G A Luzzi

  • 1Nuffield Department of Clinical Medicine, John Radcliffe Hospital, Headington, Oxford, UK.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|January 1, 1990
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep immune profiling of endometrial and peripheral blood cells in endometriosis.

Human reproduction (Oxford, England)·2026
Same author

Transcriptomic response and immunological responses to chimpanzee adenovirus- and MVA viral-vectored vaccines for RSV in healthy adults.

Clinical and experimental immunology·2023
Same author

Coronavirus disease 2019 subphenotypes and differential treatment response to convalescent plasma in critically ill adults: secondary analyses of a randomized clinical trial.

Intensive care medicine·2022
Same author

Expression of type I interferon-associated genes at antiretroviral therapy interruption predicts HIV virological rebound.

Scientific reports·2022
Same author

Identification of neutralising pembrolizumab anti-drug antibodies in patients with melanoma.

Scientific reports·2021
Same author

Mucosal-associated invariant T (MAIT) cells are activated in the gastrointestinal tissue of patients with combination ipilimumab and nivolumab therapy-related colitis in a pathology distinct from ulcerative colitis.

Clinical and experimental immunology·2020
Same journal

Corrigendum to "Ruyiping extract reduces lung metastasis in triple negative breast cancer by regulating macrophage polarization" [Biomed. Pharmacother. 141 (2021) 111883].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Microfluidic human liver slices reveal antifibrotic effects of liraglutide via HSC deactivation and ECM remodeling.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Corrigendum to "Targeting PD-L1 and disrupting Siglec-9 cooperatively potentiate macrophage phagocytosis of breast cancer via a trispecific macrophage engager (TriME)" [Biomed. Pharmacother. 200 (2026), 119609].

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Targeted attenuation of liver fibrosis using microbubble-enhanced protease-activated receptor 1 chimeric antigen receptor T cells.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

Euphol targets key oncogenic processes and promotes chemoprevention in organoid and In Vivo models of colorectal cancers.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
Same journal

CAR-T cell therapy and oncolytic viruses: A synergic approach for advanced GI cancers.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie·2026
See all related articles

Acyclovir treatment for herpes zoster (HZ) benefits acute illness but does not consistently prevent postherpetic neuralgia (PHN). Evidence suggests limited long-term impact of oral acyclovir on PHN development.

Area of Science:

  • Infectious Diseases
  • Neurology
  • Pharmacology

Background:

  • Acyclovir is established for treating acute herpes zoster (HZ) illness.
  • The impact of acyclovir on preventing postherpetic neuralgia (PHN) remains controversial.
  • Previous studies show mixed results regarding acyclovir's efficacy in PHN prevention.

Purpose of the Study:

  • To evaluate the influence of acyclovir treatment on the development of postherpetic neuralgia (PHN) after acute herpes zoster (HZ).
  • To synthesize current evidence on the effectiveness of intravenous and oral acyclovir in mitigating PHN.

Main Methods:

  • Systematic review and analysis of prospective studies and clinical trials.
  • Comparison of outcomes between patients receiving acyclovir and placebo or no treatment.

Related Experiment Videos

  • Assessment of acyclovir's effect on PHN incidence at different time points post-HZ.

    • Main Results:

    • Intravenous acyclovir showed no significant effect on PHN development in prospective studies.
    • High-dose oral acyclovir may offer a modest reduction in PHN within 3 months post-HZ, but findings are inconsistent.
    • No trials demonstrate a significant reduction in PHN from 3 months onward with oral acyclovir treatment.

    Conclusions:

    • Current evidence does not support acyclovir as a definitive preventative treatment for postherpetic neuralgia (PHN).
    • Further research is needed to clarify the role of antiviral therapy in managing long-term complications of herpes zoster (HZ).
    • The long-term efficacy of acyclovir in preventing PHN remains unproven.